Commercial-stage biopharmaceutical company InnoCare Pharma (HKEX:09969) (SSE:688428) and biotechnology company Keymed Biosciences Inc (HKEX:02162) announced on Monday that they have entered into an exclusive licence agreement with Prolium Bioscience for the development and commercialisation of ICP-B02, a CD20xCD3 bispecific antibody.
Under the terms of the deal Prolium, a Delaware company funded and backed by New York-based investment firm RTW Investments LP, will have the exclusive right to develop and commercialise ICP-B02 globally in non-oncology and in ex-Asia regions for oncology.
InnoCare and KeyMed will receive up to USD520m in milestone payments and royalties on future net sales, as well as a minority equity stake in Prolium.
ICP-B02 is a CD20xCD3 bispecific antibody jointly developed by InnoCare and KeyMed. A Phase I/II clinical trial in China is ongoing to evaluate its safety and efficacy in relapsed/refractory Non-Hodgkin lymphoma.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA